Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials

BACKGROUND: The myocardial effects of phosphodiesterase type 5 inhibitors (PDE5i) have recently received consideration in several preclinical studies. The risk/benefit ratio in humans remains unclear. METHODS: We performed a meta-analysis of randomized, placebo-controlled trials (RCTs) to evaluate t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Giannetta, Elisa, Feola, Tiziana, Gianfrilli, Daniele, Pofi, Riccardo, Dall’Armi, Valentina, Badagliacca, Roberto, Barbagallo, Federica, Lenzi, Andrea, Isidori, Andrea M
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2014
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4201993/
https://ncbi.nlm.nih.gov/pubmed/25330139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-014-0185-3
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi